X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
heterozygous familial hypercholesterolemia (183) 183
humans (147) 147
index medicus (113) 113
hypercholesterolemia (70) 70
cholesterol (68) 68
male (59) 59
female (56) 56
statins (56) 56
cardiac & cardiovascular systems (54) 54
lipids (54) 54
monoclonal-antibody (54) 54
density-lipoprotein cholesterol (51) 51
cholesterol, ldl - blood (48) 48
subtilisin/kexin type 9 (47) 47
atherosclerosis (46) 46
cardiovascular disease (43) 43
low density lipoproteins (42) 42
middle aged (42) 42
coronary-heart-disease (40) 40
anticholesteremic agents - therapeutic use (39) 39
pharmacology & pharmacy (38) 38
risk factors (37) 37
antibodies, monoclonal - therapeutic use (36) 36
pcsk9 (35) 35
adult (34) 34
biochemistry & molecular biology (34) 34
hypercholesterolemia - drug therapy (33) 33
peripheral vascular disease (33) 33
double-blind (32) 32
hydroxymethylglutaryl-coa reductase inhibitors - therapeutic use (32) 32
hyperlipoproteinemia type ii - genetics (32) 32
evolocumab amg 145 (31) 31
mutation (31) 31
low density lipoprotein (29) 29
low-density-lipoprotein (29) 29
proprotein convertase 9 (29) 29
animals (26) 26
receptors, ldl - genetics (26) 26
ldl-c (25) 25
treatment outcome (25) 25
familial hypercholesterolemia (24) 24
genetic aspects (24) 24
ldl cholesterol (24) 24
lipoproteins (24) 24
medicine, general & internal (24) 24
monoclonal antibodies (24) 24
placebo-controlled trial (24) 24
proprotein convertase 9 - antagonists & inhibitors (24) 24
research (24) 24
hyperlipoproteinemia type ii - blood (23) 23
hyperlipoproteinemia type ii - drug therapy (23) 23
statin therapy (23) 23
cardiovascular-disease (22) 22
care and treatment (22) 22
efficacy (22) 22
safety (22) 22
adolescent (21) 21
alirocumab (21) 21
diagnosis (21) 21
heart-disease (21) 21
therapy (21) 21
cardiovascular diseases (20) 20
familial hypercholesterolaemia (20) 20
medicine, research & experimental (20) 20
aged (19) 19
child (19) 19
medicine & public health (19) 19
randomized controlled-trial (19) 19
coronary heart disease (18) 18
evolocumab (18) 18
heterozygous familial hypercholesterolaemia (18) 18
hypolipidemic agents - therapeutic use (18) 18
ldl receptor (18) 18
cholesterol - blood (17) 17
heterozygote (17) 17
review (17) 17
risk (17) 17
antibodies, monoclonal - adverse effects (16) 16
pediatrics (16) 16
proprotein convertases - antagonists & inhibitors (16) 16
statin-intolerant patients (16) 16
cardiovascular diseases - prevention & control (15) 15
clinical trials (15) 15
dyslipidemia (15) 15
patients (15) 15
proprotein convertase subtilisin (15) 15
cardiology (14) 14
drug therapy (14) 14
genetics & heredity (14) 14
hyperlipidemia (14) 14
mortality (14) 14
phenotype (14) 14
proprotein convertase subtilisin/kexin type 9 (14) 14
serine-protease (14) 14
statin (14) 14
anticholesteremic agents (13) 13
apolipoprotein-b (13) 13
cardiovascular (13) 13
coronary artery disease (13) 13
disease (13) 13
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


European heart journal, ISSN 0195-668X, 2015, Volume 36, Issue 43, pp. 2996 - 3003
Journal Article
Atherosclerosis, ISSN 0021-9150, 10/2018, Volume 277, pp. 377 - 382
Familial hypercholesterolaemia (FH) is an autosomal-dominant disorder associated with high low-density lipoprotein cholesterol (LDL-C). Left untreated, 50% of... 
Advocacy | Avoidable | Familial hypercholesterolaemia | Prevent | Heterozygous | Undiagnosed | Families | Children | Patients | Homozygous | FH | CARDIAC & CARDIOVASCULAR SYSTEMS | DISEASE | PERIPHERAL VASCULAR DISEASE | Genetic aspects | Hypercholesterolemia | Coronary heart disease | Low density lipoproteins | Cardiac patients | Patient advocacy
Journal Article
Atherosclerosis, ISSN 0021-9150, 11/2019, Volume 290, pp. 1 - 8
This consensus statement on the management of children and young people with heterozygous familial hypercholesterolaemia (FH) addresses management of... 
Children and young people | Statin treatment | Heterozygous familial hypercholesterolaemia | Familial hypercholesterolaemia | Lifestyle advice
Journal Article
Paediatrics and International Child Health, ISSN 2046-9047, 10/2016, Volume 36, Issue 4, pp. 243 - 247
Homozygous familial hypercholesterolaemia (HoFH) is an inherited disease causing an approximately fourfold increase in blood low-density lipoprotein... 
HeFH, heterozygous familial hypercholesterolaemia, is caused by one mutant allele of genes affecting LDLR activity | ADH, autosomal dominant hypercholesterolaemia, refers to hypercholesterolaemia owing to a single mutation of an allele of a gene affecting LDLR activity | PCSK9, a protein called proprotein convertase subtilisin/kexin type 9, increases the rate of degradation of LDLR | Lomitapide | APOB, apolipoprotein B, is the main protein component of LDL and is the ligand for LDL receptors in the liver | FH, familial hypercholesterolaemia, is an inherited condition causing reduced LDLR activity with consequent hypercholesterolaemia | PCSK9 | LDLRAP1, a protein called LDLR adaptor protein 1, facilitates LDLR function | Lipoprotein apheresis | Microsomal triglyceride transfer protein is an enzyme involved in the hepatic assembly of triglyceride, cholesterol and APOB into triglyceride-rich particles which are secreted by the liver. These particles are metabolised to LDL | Evolucomab | LDL, low-density lipoprotein, is a complex of cholesterol attached to a lipoprotein particle which is removed from blood mainly by the liver | Homozygous familial hypercholesterolaemia | HoFH, homozygous familial hypercholesterolaemia is caused by two mutant alleles of genes affecting LDLR activity | ARH, autosomal recessive hypercholesterolaemia, refers to hypercholesterolaemia owing to a mutation of both alleles of a single gene affecting LDLR activity | LDLR, LDL receptors, mediate LDL uptake by the liver | LDLC, LDL cholesterol, refers to the cholesterol component of LDL | Liver transplantation | PEDIATRICS | Hyperlipoproteinemia Type II - complications | Atherosclerosis - etiology | Hyperlipoproteinemia Type II - therapy | Anticholesteremic Agents - therapeutic use | Atherosclerosis - therapy | Humans | Hyperlipoproteinemia Type II - diagnosis | Organ Transplantation
Journal Article
Atherosclerosis, ISSN 0021-9150, 03/2018, Volume 270, pp. 117 - 122
Journal Article
Atherosclerosis (Supplements) (Component), ISSN 1567-5688, 04/2017, Volume 26, pp. 25 - 35
Journal Article
Journal Article
Current Cardiovascular Risk Reports, ISSN 1932-9520, 2/2015, Volume 9, Issue 2, pp. 1 - 9
Journal Article
European Journal of Clinical Investigation, ISSN 0014-2972, 02/2010, Volume 40, Issue 2, pp. 89 - 94
Journal Article
Atherosclerosis, ISSN 0021-9150, 11/2019, Volume 290, pp. 44 - 51
In 2008, the National Institute of Health and Care Excellence in the UK recommended that patients undergoing lipoprotein apheresis (LA) should be included in... 
Cardiovascular events | Heterozygous familial hypercholesterolaemia | Lipoprotein (a) | Lipoprotein apheresis | Homozygous familial hypercholesterolaemia
Journal Article